Headline numbers rarely match what you actually pay. Four cost models.
The four cost models
- Cash-pay compounded. $145–$269/mo. Flat-rate (NexLife $145–$215) holds through titration; dose-step raises prices.
- Insurance + branded. Best case: $25–$100/mo copay. Worst case: list ($1,000–$1,350/mo).
- Insurance-leveraged programs. Form Health, Calibrate, Sequence — $99–$200/mo program fee plus copay.
- Manufacturer cash-pay. Lilly Direct Zepbound vial from ~$349/mo. NovoCare Wegovy ~$499/mo.
Hidden costs
- Lab work ($50–$200)
- Consultation fees if billed separately
- Shipping ($10–$25 if not included)
- Antiemetics during early titration
Year 1 spend
| Path | Year 1 |
|---|---|
| NexLife sema (12-mo) | $1,740 |
| NexLife tirz (12-mo) | $2,232 |
| Hims sema | $2,388 |
| Branded Wegovy + good insurance | $300–$1,200 |
| Branded Wegovy list (no coverage) | $16,000+ |
| NovoCare Wegovy cash-pay | $5,988 |
How to minimize
- Check insurance for GLP-1 coverage.
- If covered: pursue branded.
- If uncovered: flat-rate cash-pay compounded typically lowest annual cost.
- Avoid dose-step programs unless maintenance fits budget.